- Home
- ESPR vs GPAT Comparison
ESPR vs GPAT Comparison
Compare ESPR & GPAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- GPAT
- Stock Information
- Founded
- ESPR 2008
- GPAT 2020
- Country
- ESPR United States
- GPAT United States
- Employees
- ESPR N/A
- GPAT N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- GPAT
- Sector
- ESPR Health Care
- GPAT
- Exchange
- ESPR Nasdaq
- GPAT NYSE
- Market Cap
- ESPR 305.0M
- GPAT 365.5M
- IPO Year
- ESPR 2013
- GPAT 2024
- Fundamental
- Price
- ESPR $1.50
- GPAT $10.27
- Analyst Decision
- ESPR Buy
- GPAT
- Analyst Count
- ESPR 7
- GPAT 0
- Target Price
- ESPR $6.36
- GPAT N/A
- AVG Volume (30 Days)
- ESPR 3.5M
- GPAT 18.5K
- Earning Date
- ESPR 03-04-2025
- GPAT 01-01-0001
- Dividend Yield
- ESPR N/A
- GPAT N/A
- EPS Growth
- ESPR N/A
- GPAT N/A
- EPS
- ESPR N/A
- GPAT 0.30
- Revenue
- ESPR $332,314,000.00
- GPAT N/A
- Revenue This Year
- ESPR $5.51
- GPAT N/A
- Revenue Next Year
- ESPR $1.42
- GPAT N/A
- P/E Ratio
- ESPR N/A
- GPAT $33.96
- Revenue Growth
- ESPR 185.66
- GPAT N/A
- 52 Week Low
- ESPR $1.47
- GPAT $9.98
- 52 Week High
- ESPR $3.94
- GPAT $10.30
- Technical
- Relative Strength Index (RSI)
- ESPR 34.95
- GPAT N/A
- Support Level
- ESPR $1.57
- GPAT N/A
- Resistance Level
- ESPR $1.86
- GPAT N/A
- Average True Range (ATR)
- ESPR 0.13
- GPAT 0.00
- MACD
- ESPR -0.01
- GPAT 0.00
- Stochastic Oscillator
- ESPR 7.69
- GPAT 0.00
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About GPAT GP-ACT III ACQUISITION CORP
GP-Act III Acquisition Corp is a blank check company.